Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02140281 · ClinicalTrials.gov registry record · Phase 1
To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers
A Phase 1 study, sponsored by Ardelyx.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT02140281 is a Phase 1 study that has completed, run by Ardelyx. The registered enrollment target is 71 participants.
The verdict
NCT02140281, a Phase 1 study, has completed, sponsored by Ardelyx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
A study to evaluate the effect of repeated oral doses of AZD1722 on the pharmacokinetics of Cefadroxil
Interventions
- DRUG Treatment A (cefadroxil alone)
- DRUG Treatment B - AZD1722 followed by cefadroxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2014-05 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02140281
The ClinicalTrials.gov registry entry for NCT02140281 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardelyx, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Treatment A (cefadroxil alone) is the first listed.
NCT02140281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02140281 about?
NCT02140281 is a clinical study titled "To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers". A study to evaluate the effect of repeated oral doses of AZD1722 on the pharmacokinetics of Cefadroxil
What is the current status of trial NCT02140281?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2014-05. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02140281?
The interventions under investigation include: Treatment A (cefadroxil alone) (DRUG), Treatment B - AZD1722 followed by cefadroxil (DRUG).
Who is sponsoring clinical trial NCT02140281?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.